Oncopeptides AB (LTS:0RN4)
kr 1.654 0 (0%) Market Cap: 349.01 Mil Enterprise Value: 216.16 Mil PE Ratio: 0 PB Ratio: 2.59 GF Score: 54/100

Oncopeptides AB to Discuss Positive Topline Results From the Phase 3 OCEAN Call Transcript

May 25, 2021 / 09:00AM GMT
Release Date Price: kr81.49 (-7.37%)
Operator

Hello, and welcome to the Oncopeptides (technical difficulty) conference 2021. (Operator Instructions)

Today, I'm pleased to present CEO, Marty Duvall. Please go ahead with your meeting.

Martin J. Duvall;publ;CEO
Oncopeptides AB

()-

Thank you very much and good morning to everyone, and thank you for joining us on this great occasion to provide the top line results for our Phase III OCEAN trial. We're very excited to communicate our thoughts and the top line results and implications for this fantastic outcome of a head-to-head comparison.

So on Slide 2, I will be joined today by Jakob Lindberg, our Chief Scientific Officer; by Klaas Bakker, our Chief Medical Officer; and by Anders Martin-Löf, our Chief Financial Officer. And as far as the next slide and on disclaimers, of course, we will be making speculative and forward-looking statements regarding our drug and our company. So we ask you to please look at our filings for the full risks and balances. So Slide 4. We're just so pleased to report these very

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot